| Literature DB >> 34993251 |
Tengfei Yang1, Bo Zhao2, Dongmei Pei1.
Abstract
PURPOSE: To evaluate the predictive effect of different obesity markers on the risk of developing type 2 diabetes in a population of healthy individuals who underwent physical examination and to provide a reference for the early detection of individuals at risk of diabetes.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34993251 PMCID: PMC8727144 DOI: 10.1155/2021/6503339
Source DB: PubMed Journal: J Diabetes Res Impact factor: 4.011
Comparison of baseline characteristics between the T2DM and non-T2DM groups.
| Variables | Non-T2DM cases ( | Incident T2DM cases ( |
|
|
|---|---|---|---|---|
| Age | 42 (37-50) | 46 (41-52.75) | -7.53 |
|
| Sex | ||||
| Men | 8022 (54.08%) | 87 (23.39%) | 137.34 |
|
| Women | 6812 (45.92%) | 285 (76.61%) | ||
| Smoke | ||||
| No | 8713 (58.73%) | 144 (38.71%) | 111.21 |
|
| Yes | 6121 (41.27%) | 288 (61.29%) | ||
| Alcohol consumption | ||||
| No | 11321 (76.32%) | 266 (71.50%) | 4.64 | 0.03 |
| Yes | 3512 (23.68%) | 106 (28.50%) | ||
| Sports | ||||
| No | 12221 (82.39%) | 321 (86.29%) | 3.83 | 0.05 |
| Yes | 2613 (17.61%) | 51 (13.71%) | ||
| SBP (mmHg) | 113 (103.5-124) | 121.5 (112-132) | -9.52 |
|
| DBP (mmHg) | 71 (64-78) | 76.5 (70-84) | -10.29 |
|
| ALT (U/L) | 17 (13-23) | 24 (18-39) | -14.82 |
|
| AST (U/L) | 17 (14-21) | 20 (16-26) | -9.13 |
|
| GGT (U/L) | 15 (11-22) | 24 (17-36.75) | -13.68 |
|
| TG (mmol/L) | 0.73 (0.5-1.11) | 1.22 (0.86-1.93) | -14.87 |
|
| TC (mmol/L) | 5.07 (4.5-5.66) | 5.43 (4.81-6) | -6.80 |
|
| HDL-C (mmol/L) | 1.42 (1.17-1.71) | 1.13 (0.96-1.32) | -14.43 |
|
| Anthropometric indices | ||||
| BMI | 21.8 (19.96-23.89) | 24.67 (22.29-27.25) | -15.18 |
|
| VAI | 0.73 (0.46-1.24) | 1.52 (0.92-2.53) | -15.84 |
|
| BRI | 2.64 (2.11-3.24) | 3.52 (2.85-4.29) | -15.83 |
|
| LAP | 9.77 (4.88-19.18) | 26.9 (14.33-47.07) | -17.09 |
|
| WHtR | 0.46 (0.43-0.49) | 0.51 (0.47-0.55) | -15.83 |
|
Figure 1ROC curves of five obesity evaluation markers for predicting the onset of type 2 diabetes.
ROC curve results of five obesity evaluation markers for predicting new-onset type 2 diabetes.
| AUC (95% CI) | Cutoff | Sensitivity (%) | Specificity (%) |
|
| |
|---|---|---|---|---|---|---|
| VAI | 0.740 (0.733-0.747) | 1.044 | 0.718 | 0.677 | 2.471 | 0.014 |
| BRI | 0.740 (0.733-0.747) | 3.289 | 0.605 | 0.766 | 2.047 | 0.041 |
| BMI | 0.730 (0.723-0.737) | 23.521 | 0.629 | 0.713 | 3.035 | 0.002 |
| LAP | 0.759 (0.752-0.766) | 16.044 | 0.723 | 0.689 | ||
| WHtR | 0.740 (0.733-0.747) | 0.496 | 0.605 | 0.766 | 2.047 | 0.041 |
BRI vs. BMI: Z = 1.445, P = 0.148; BRI vs. VAI: Z = 0.007, P = 0.994; BMI vs. VAI: Z = 0.682, P = 0.495; WHtR vs. BMI: Z = 1.445, P = 0.148; WHtR vs. BRI: Z = 0, P = 1; WHtR vs. VAI: Z = 0.007, P = 0.994.
Results of Cox proportional risk regression model analysis of the relationship between different obesity markers and the development of T2DM.
| New cases/total ( | Incidence density (%) | Model 1 | Model 2 | Model 3 | |
|---|---|---|---|---|---|
| LAP | |||||
| Q1 (<4.97) | 27/3821 | 0.71 | 1 | 1 | 1 |
| Q2 (4.97-10) | 36/3796 | 0.95 | 1.39 (0.85-2.29)∗ | 1.2 (0.73-1.99)∗ | 1.09 (0.66-1.81)∗ |
| Q3 (10-19.76) | 76/3795 | 2 | 2.91 (1.88-4.51) | 2.23 (1.42-3.48) | 1.78 (1.13-2.81) |
| Q4 (>19.76) | 233/3794 | 6.14 | 8.56 (5.75-12.75) | 6.1 (4.02-9.25) | 3.94 (2.55-6.09) |
|
| <0.001 | <0.001 | <0.001 | ||
| VAI | |||||
| Q1 (<0.46) | 30/3799 | 0.79 | 1 | 1 | 1 |
| Q2 (0.46-0.74) | 34/3799 | 0.89 | 0.97 (0.59-1.58)∗ | 0.86 (0.52-1.4)∗ | 0.78 (0.48-1.27)∗ |
| Q3 (0.74-0.1.26) | 88/3799 | 2.32 | 2.44 (1.61-3.7) | 1.94 (1.28-2.95) | 1.59 (1.04-2.42) |
| Q4 (>1.26) | 220/3798 | 5.79 | 6 (4.1-8.79) | 4.23 (2.86-6.26) | 2.85 (1.91-4.25) |
|
| <0.001 | <0.001 | <0.001 | ||
| BRI | |||||
| Q1 (<2.12) | 27/3802 | 0.71 | 1 | 1 | 1 |
| Q2 (2.12-2.65) | 44/3801 | 1.16 | 1.79 (1.11-2.9)∗ | 1.55 (0.96-2.51)∗ | 1.43 (0.88-2.32)∗ |
| Q3 (2.65-3.26) | 75/3802 | 1.97 | 2.99 (1.93-4.64) | 2.26 (1.44-3.53) | 1.8 (1.14-2.83) |
| Q4 (>3.26) | 226/3801 | 5.95 | 9.59 (6.43-14.29) | 6.77 (4.49-10.2) | 4.5 (2.93-6.91) |
|
| <0.001 | <0.001 | <0.001 | ||
| BMI | |||||
| Q1 (<19.99) | 26/3803 | 0.68 | 1 | 1 | 1 |
| Q2 (19.99-21.86) | 50/3800 | 1.32 | 1.87 (1.16-3)∗ | 1.59 (0.99-2.56)∗ | 1.44 (0.89-2.32)∗ |
| Q3 (21.86-23.97) | 87/3802 | 2.29 | 3.22 (2.08-4.99) | 2.42 (1.55-3.79) | 2 (1.27-3.15) |
| Q4 (>23.97) | 209/3801 | 5.5 | 7.93 (5.28-11.92) | 5.92 (3.89-9.01) | 3.87 (2.49-6.01) |
|
| |||||
| WHtR | |||||
| Q1 (<0.42) | 27/3802 | 0.71 | 1 | 1 | 1 |
| Q2 (0.42-0.46) | 44/3801 | 1.16 | 1.79 (1.11-2.9)∗ | 1.55 (0.96-2.51)∗ | 1.43 (0.88-2.32)∗ |
| Q3 (0.46-0.49) | 75/3802 | 1.97 | 2.99 (1.93-4.64) | 2.26 (1.44-3.53) | 1.8 (1.14-2.83) |
| Q4 (>0.49) | 226/3801 | 5.95 | 9.59 (6.43-14.29) | 6.77 (4.49-10.2) | 4.5 (2.93-6.91) |
|
| <0.001 | <0.001 | <0.001 |
Model 1: unadjusted; Model 2: adjusted for age, sex, smoke, and alcohol; Model 3: adjusted for model 2 plus ALT, AST, GGT, SBP, and DBP. ∗P > 0.05.
Figure 2Cumulative prevalence of type 2 diabetes mellitus (T2DM) according to the lipid accumulation index (LAP) quartile groups.